cupric chloride has been researched along with Experimental Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Tamimi, J; Alhazza, IM; Aman, S; Ebaid, H; Hassan, I; Khan, AA; Qamar, W; Rady, AM | 1 |
| Cui, J; Guo, W; Hao, Y; Li, C; Li, Y; Wang, C; Wang, J; Wang, Y; Zhang, H; Zhang, L | 1 |
2 other study(ies) available for cupric chloride and Experimental Neoplasms
| Article | Year |
|---|---|
Restrained management of copper level enhances the antineoplastic activity of imatinib in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Survival; Chemotherapy, Adjuvant; Copper; Disulfiram; Drug Synergism; Imatinib Mesylate; Metabolism; Neoplasms, Experimental; Rats; Treatment Outcome | 2018 |
Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Cholesterol; Copper; Copper Sulfate; Drug Compounding; Half-Life; Hydrogen-Ion Concentration; Injections, Intravenous; Ionophores; Liposomes; Male; Mice; Mitoxantrone; Neoplasms, Experimental; Nigericin; Phosphatidylcholines; Quaternary Ammonium Compounds; Solubility; Spectrum Analysis; Technology, Pharmaceutical | 2008 |